Chimeric antigen receptor T in the treatment of multiple myeloma – state of the art and future directions by Dytfeld, Dominik
120
Chimeric antigen receptor T in the 
treatment of multiple myeloma –  
state of the art and future directions
Department of Hematology and Bone Marrow 









In spite of the introduction of several new drugs in the last 10 years, multiple myeloma (MM) remains incurable. Thus, an adoptive 
cellular therapy using chimeric antigen receptor T (CART), a strategy to increase the frequency of tumor-directed and functionally active 
T cells targeting antigens present on the cancer cell, might change the treatment in MM as it did in lymphoma and ALL. There are several 
targets for CART therapy in MM on different levels of development, which are discussed in the manuscript. B-cell maturation antigen 
(BCMA) being tested in the studies of phase 1–2 is the most promising, but so far CART has not been approved in the cure of MM and 
remains an experimental approach. The hematological society is facing a new technology which with its potential ability to cure MM, in 
spite of its complexity, cost, and toxicity, will definitely and soon change the landscape of myeloma in Europe and world-wide.
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Introduction
Multiple myeloma (MM) is diagnosed in around 1,600 new cases per 
year in Poland, with estimated population exceeding 10,000, despite 
recent improvements in treatment including proteasome inhibitors, 
immunomodulatory drugs, and monoclonal antibodies remains 
incurable and is associated with a high mortality rate [1]. In recent 
years, the development of immunotherapy has revolutionized the 
treatment of cancer. Therapeutic agents that induce the patients’ 
immune system to activate the ability to kill tumor cells and to overcome 
the immunosuppressive mechanisms of the tumor microenvironment 
may improve clinical results. In this setting, cellular therapy using 
chimeric antigen receptor (CAR) might change significantly the 
treatment strategy for MM. CARs are artificial fusion proteins that 
incorporate an antigen recognition domain. T-cells expressing a CAR 
(CARTs) can precisely recognize a targeted antigen, which is an 
advantage over nonspecific cellular therapies such as allogeneic 
stem cell transplantation [2]. Additionally, to recognize the domain, 
CAR includes transmembrane region, one of two types of signaling 
domains (CD28 or 4-1BB) and T-cell activation domain (CD3ζ). 
Signaling region was introduced in the second generation of CARTs, 
which significantly improved the efficacy and the safety profile of this 
technology. Second generation CARTs are at the advanced stage 
of investigation, which led to the registration of antiCD19 CARTs for 
the treatment of relapsed or refractory B-cell acute lymphoblastic 
leukemia (B-ALL) in pediatric and young adults, and for diffuse large 
B-cell lymphoma (DLBCL) by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA). The first infusion 
in Poland was on November 28, 2019 [3, 4]. So far, there is no CART 
formally approved either by EMA or by FDA for the treatment of MM, 
but several constructs are being investigated. High efficacy of CART is 
unfortunately associated with life-threating toxicities. These toxicities 
include cytokine release syndrome (CRS) that manifests with fever, 
hypotension, and tachycardia; and immune effector cell-associated 
neurotoxicity syndrome (ICANS), which is related to different stages 
of encephalopathy including coma. CRS has been described to be 
more severe in patients with high disease burden and is associated 
with increase of serum cytokines such as interleukin 6 (IL-6) and 
interferon γ (IFN-γ). The treatment includes supportive care and 
the use of tocilizumab (IL-6 receptor antagonist) and steroids. Both 
ICANS and CRS are usually transient and fully reversible.
Antigen selection
One of the most important goals of the development of CART 
technology is to improve the efficacy-to-toxicity ratio, which can be 
achieved by improved construct of the receptor and the right choice of 
target. Thus, several different antigens are evaluated to understand the 
feasibility of introduction of CART in MM.
CD70
CD70, known as CD27 ligand, might be a good candidate for CART 
therapy in MM, as its presence is limited to lymphoid tissue when 
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administered. It is under investigation as a target in MM but has not 
been used in the clinical setting yet [5].
CD56
CD56 is surface glycoprotein mediating cell to matrix interactions. 
The construct of CART using CD56 as a target was assessed 
in preclinical studies; however, its potential neurotoxicity is 
a significant limitation to further studies [6].
CD38
CD38 is a transmembrane glycoprotein playing a significant role in 
cell adhesion and calcium metabolism. It is expressed on B cells, 
plasma cells, as well as natural killer (NK) cells and T cells. It is 
also present on prostate, muscles, and red blood cells. Despite the 
presence of CD38 on hematopoietic cells, due to the high efficacy of 
daratumumab and isatuximab (monoclonal antibodies with specificity 
to CD38), proven in clinical studies in MM, this antigen is a target 
for CART constructed with caspase-9 suicide gene and it is under 
investigation in preclinical setting [7].
CD138
CD138, known as syndecan-1, is heparin-sulfate proteoglycan 
present on plasma cells. Its expression on resistant cells is higher 
in newly diagnosed MM is the notable important characteristic. 
CART anti-CD138 was tested in phase 1 study in 6 patients with 
advanced disease. Four of them achieved stable disease  (SD) and 
1 progression (PD). Toxicity of the treatment was limited [8, 9].
CD19
Several studies suggested the significant role of cancer stem cells 
in the mechanism of the resistance in MM. It is postulated that 
CD138-CD45+CD19+CD20+ cells may elevate MM colonies and 
are considered as MM stem cells. Taking that into consideration, 
CART against CD19 was used in patients who failed to respond to 
high-dose therapy (autologous peripheral stem cell transplantation 
[auto-PBSCT]). Approximately 12–14 days after the second 
auto-PBSCT, 5 × 107 anti-CD19 autologous CART were infused. Out 
of 12 patients enrolled for the study, 10 patients who received CART 
have progressed with median progression-free survival (PFS) of 
185 days [10].
Kappa light chain
Since some of the MM cells expressed light chains on the cell 
surface, construct of CART directed against kappa was used in 
phase 1 study in patients with relapsed/refractory MM (RRMM). 
Such construct was used in 7 patients with active MM. In those, 3 of 
them received salvage chemotherapy within 4 weeks before CART 
infusion, whereas those who did not receive chemotherapy and had 
lymphocyte count above 500/µl received cyclophosphamide. The 
best response was SD in 4 and PD in 3 patients [11].
Signaling lymphocyte-activating molecule F7
One of the most promising molecules targeted for immunotherapy is 
signaling lymphocyte-activating molecule F7 (SLAMF7), known also 
as a CD319 or CS1. It is present on the surface of plasma cells, 
dendritic cells, NK, and T cells [12]. As elotuzumab – monoclonal 
antibody directed against this antigen showed good results in 
combination with lenalidomide and pomalidomide in RRMM, this 
antigen is under investigation as a target for CART. An argument for 
such construct is lack of expression of SLAMF7 on non-hematological 
cells. In phase 1–2 study, CART against SLAMF7 with sleeping 
beauty transposon that can be stopped by rimiducin is investigated in 
RRMM (clinicaltrial.gov identifier: NCT03958656).
B-cell maturation antigen
B-cell maturation antigen (BCMA, also named TNFRSF17 or CD269) 
belongs to the family of tumor necrosis factors. It is present on plasma 
cells, but not on hematopoietic stem cells. Considering the strong 
expression of the BCMA on malignant plasma cells and its important 
mechanism of action, BCMA represents an ideal therapeutic target 
for CART therapy. In fact, the majority of CART constructs tested in 
clinical trials in MM are targeting BCMA.
There are two most advanced CARTs against BCMA in MM, which 
seem to be close to registration, which is expected by 2021: the first 
is bb2121 developed by Celgene/BMS and the second is JNJ-4528 
by Janssen. Both are second generation CARTs but have slightly 
different design–bb2121 has one binding domain, whereas JNJ4528 
has two (Fig. 1), which might have an impact on their efficacy and 
safety profile.
Bb2121 was investigated in phase 1 study with different doses of 
CART (50–800 × 106 cells). All 33 patients had previously received 
both bortezomib and lenalidomide, and 79% were exposed 
to bortezomib, carfilzomib, lenalidomide, pomalidomide, and 
daratumumab. A total of 26 patients (79%) were refractory to both 
a proteasome inhibitor and an immunomodulatory agent; 6 patients 
(18%) were refractory to bortezomib, carfilzomib, lenalidomide, 
pomalidomide, and daratumumab. After 6.2 months of observation, 
85% of the patients achieved an objective response (at least SD). 
A total of 6 out of 15 patients who reached complete response have 
relapsed. The median PFS was 11.8 months for the active dose 
(150–800) and 2.7 for inactive dose (50), and the curve did not 
achieve plateau phase. All 16 patients who had a response (partial 
response or better) and who could be evaluated for minimal residual 
disease (MRD) had MRD-negative status with a sensitivity 10-4. 
Hematologic toxicities were the most common events of grade (G) 3 
or higher, including neutropenia (in 85% of the patients), leukopenia 
(in 58%), anemia (in 45%), and thrombocytopenia (in 45%). Around 
76% had CRS, but mostly low grade. G3 (not seen in G4 or 5) was 
present in 2 patients only. ICANS was seen in 14 patients (42%), 
mostly G3. Only one patient experienced G4 reversible neurotoxicity 
[13]. In the phase 2 study that was assessing efficacy of bb2121 
(KarMMA study) in 140 patients with RRMM in different doses (150–
450 × 106 cells) at least partial response (PR) was seen in 73.4% 
patients. The point of significance is the response was better in 
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higher doses (ORR for 150 × 106 was 50%, 68.6% for 300 × 106, 
and 81.5 for 450 × 106). In another study, bb2121 was remodeled 
by the introduction of P13K inhibitor to enrich the drug product for 
memory-like T cells called as bb21217. After treatment of bb21217, 
13 out of 22 patients developed mild CRS and only 1 developed G3. 
Five patients experienced ICANS but only one in G3 and one G4. 
Out of the evaluable 18 patients, 15 (83%) patients had response but 
eventually only 6 of them progressed [14].
A first-in-human phase 1 study (LEGEND-2) conducted in China of 
LCAR-B38M, an identical CAR to JNJ-4528, showed high overall 
response and manageable safety in 74 patients with RR MM. This 
construct is being assessed in phase 1b/2 CARTITUDE-1 study 
conducted in the US. Patients who were enrolled to this study had 
received a median of 5 (range 3–18) prior lines of treatment, 88% 
were triple-refractory to a proteasomes’ inhibitor, immunomodulatory 
drug, and anti-CD38 antibody, 72% were penta-exposed, and 36% 
were penta-refractory. With a median follow-up of 3 months, an 
overall response rate of 91% was observed, with 4 stringent complete 
responses (sCRs), 2 CRs, 7 very good partial responses, and 6 PRs. 
Of the 15 evaluable patients, 10 were MRD-negative at the 10-5 
sensitivity level, 2 at the 10-4 sensitivity level, and 3 had unidentified 
clones. No patient had progressed at the time of data cutoff. Most 
frequently reported adverse events were CRS (88%), neutropenia 
(80%), anemia (76%), and thrombocytopenia (72%). CRS was 
mostly mild (G1-2). There was one case of G3 CRS and one G5 at 
day 99, which raised from G4. Three patients developed ICANS: two 
in G1 and G3, which resolved within 2 days [15]. Common concerns 
regarding whether soluble BCMA present in serum might affect the 
efficacy anti-BCMA CART turned out to be not true. No correlation 
between expression of BCMA and response was noticed is what the 
most important observation is in both studies. Short summary of both 
studies is shown in table I.
Fig. 1. The scheme of bb2121 and JNN4528 constructs
Table I. Comparison of two phase 1 studies assessing bb2121 and JNJ-4528 in patients with RRMM
bb2121 JNJ-4528
Investigator Raje 2019 Madduri 2019
Number of patients 33 33
Number of antigen-binding domains 1 2
Median of number of prior therapies with range 7 (3–23) 5 (3–18)
Lymphodepletion FluCy FluCy






Targeted dose: 0.75 × 106cells/kg with range 0.5–1.0 × 106
Bridging therapy allowed Yes Yes
PR + VGPR + CR 73% (all doses)
83% (150–800 × 106 cells)
91%
CRS ≥ G3 2 G3 1 G3
ICANS ≥ G3 1 G3 1 G3 and 1 G5
FluCy – fludarabine and cyclophosphamide; PR — partial response; VGPR – very good partial response; CR – complete response; CRS – cytokine release syndrome; G – grade; 
ICANS – immune effector cell-associated neurotoxicity syndrome
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CARTs directed against BCMA are also being tested with gamma 
secretase inhibitor to increase BCMA expression on MM cells. In 
phase 1 study, 7 out of 8 enrolled for the study, who were eligible 
for evaluation, achieved at least PR and 5 out of 6 achieved MRD 
negativity. One patient died due to CRS [16].
Biclonal CART
Another way to improve efficacy is to combine two CARTs or use 
biclonal designs. The first approach was tested with anti-CD19 and 
anti-BCMA CARTs that were infused sequentially in 28 patients 
with RRMM. In all, 92% achieved at least PR, with median PFS of 
8 months and median overall survival (OS) was 16 months. The 
treatment was well tolerated [17]. Biclonal constructs (anti-CD19 and 
BCMA) were tested in phase 1 study. All 5 patients that received it 
responded with no significant side effects (mild CRS was seen in 
2 cases, no ICANS was observed) [18].
Summary and future directions
CART in MM is an emerging strategy that will definitely change the 
landscape of MM treatment in the near future. Available data on 
efficacy of CART in MM is limited mostly to one antigen (BCMA), 
with relatively short observation. Results so far are very promising 
in terms of unforeseen overall response rate reaching 90% in 
very advanced disease and toxicity much lower than that seen in 
lymphomas. Unfortunately, PFS curves do not reach plateau phase 
and thus CART, at least as of now, cannot be considered as curative 
method in MM. Definitely more data is needed to define the role of 
CART in the strategy of MM treatment. CART technology is being 
developed both in the research labs by improving CART constructs, 
as well as in the clinic by finding an optimal way to use it – probably 
in earlier stages of the disease with possible intention to treat. There 
are plenty of unanswered questions, but more than 70 recruiting 
studies focused on CART in MM, in different stages of the disease, 
in different construct including bi- and trispecific CARs will answer 
at least some of them. It should be kept in mind that CART is by far 
one of the most expensive therapies for hematologic malignancies, 
which needs to be included in long-term health policy planning. There 
is a strong interest in MM society as how, where, and on whom the 
CART therapy will be used. For sure academic studies on CART in 
MM are needed [19].
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